Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.
Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.
Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.
Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.
Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.
Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.
Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.
Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.
Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.
Tufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.
Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.
Surbhi Sidana, MD, discusses the feasibility of administering idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma with renal impairment.
Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.
Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.
Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.
Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.
Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.
Akash Mukherjee, MD, discusses the importance of understanding disease biology when attempting to individualize treatment approaches in mantle cell lymphoma.
Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.
Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.
Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.
Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.
Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.
Ryan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.
Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..
Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.
Michael C. Haffner, MD, PhD, explains the genomic differences between prostate adenocarcinoma of the prostate and prostatic basal cell carcinoma, an extremely rare disease.
Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.
Kyle A. Blum, MD, MS, says that patients with renal medullary carcinoma have poor prognosis, but anecdotal evidence suggests that survival outcomes may be improving.
Kyle A. Blum, MD, MS, discusses how few physicians have experience with renal medullary carcinoma, and the disease often presents with nonspecific symptoms.
